- South Korea
- /
- Healthcare Services
- /
- KOSE:A008930
Returns On Capital Are Showing Encouraging Signs At Hanmi Science (KRX:008930)
What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. So on that note, Hanmi Science (KRX:008930) looks quite promising in regards to its trends of return on capital.
Understanding Return On Capital Employed (ROCE)
Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. To calculate this metric for Hanmi Science, this is the formula:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
0.057 = ₩50b ÷ (₩1.3t - ₩393b) (Based on the trailing twelve months to June 2024).
Therefore, Hanmi Science has an ROCE of 5.7%. Ultimately, that's a low return and it under-performs the Healthcare industry average of 10%.
View our latest analysis for Hanmi Science
Historical performance is a great place to start when researching a stock so above you can see the gauge for Hanmi Science's ROCE against it's prior returns. If you're interested in investigating Hanmi Science's past further, check out this free graph covering Hanmi Science's past earnings, revenue and cash flow.
What Does the ROCE Trend For Hanmi Science Tell Us?
Even though ROCE is still low in absolute terms, it's good to see it's heading in the right direction. The data shows that returns on capital have increased substantially over the last five years to 5.7%. The amount of capital employed has increased too, by 24%. The increasing returns on a growing amount of capital is common amongst multi-baggers and that's why we're impressed.
In Conclusion...
All in all, it's terrific to see that Hanmi Science is reaping the rewards from prior investments and is growing its capital base. And given the stock has remained rather flat over the last five years, there might be an opportunity here if other metrics are strong. So researching this company further and determining whether or not these trends will continue seems justified.
On the other side of ROCE, we have to consider valuation. That's why we have a FREE intrinsic value estimation for A008930 on our platform that is definitely worth checking out.
While Hanmi Science may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here.
Valuation is complex, but we're here to simplify it.
Discover if Hanmi Science might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSE:A008930
Hanmi Science
Through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally.
Proven track record with mediocre balance sheet.